Prostate Cancer Coverage from Every Angle

Adding Abiraterone Acetate Plus Prednisolone to ADT for Metastatic Prostate Cancer

By: Julia Fiederlein
Posted: Monday, November 30, 2020

In the STAMPEDE trial, patients with hormone-naive prostate cancer appeared to derive a survival advantage from androgen-deprivation therapy (ADT) in combination with abiraterone acetate plus prednisolone, according to Nicholas D. James, MBBS, PhD, of The Institute of Cancer Research, London, and colleagues. The long-term results presented during the European Society for Medical Oncology (ESMO) Virtual Congress 2020 (Abstract 611O) revealed a sustained and substantial improvement in overall survival for the subset of patients with metastatic disease.

Between November 2011 and January 2014, a total of 1,917 patients were randomly assigned in a 1:1 allocation ratio to receive either ADT alone or in combination with daily abiraterone acetate plus prednisolone. Of this study population, 52% had M1 disease. Patients with M1 tumors were stratified based on tumor burden: 48% had a high burden; 44% had a low burden; 8% had an unknown tumor burden.

The median follow-up increased from 3.5 to 6.1 years; the number of deaths after ADT alone increased from 218 to 329. The investigators reported a total of 244 deaths after ADT in combination with abiraterone acetate plus prednisolone. The 5-year survival rates were 41% with ADT alone and 60% with ADT in combination with abiraterone acetate plus prednisolone. The relative effect of abiraterone seemed to be similar among patients with low-burden (hazard ratio = 0.55) and high-burden (hazard ratio = 0.54) tumors.

At 4 years after randomization, both treatment methods appeared to exhibit similar safety profiles. Toxicities of grade 3 or higher were reported in 16% of patients in each group.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.